ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome Guidelines

  


Authors: Goyal, A.; O'Leary, D.; Dabaja, B.; Weng, W. K.; Zain, J.; Cutler, C.; Guitart, J.; Kim, Y. H.; Geskin, L. J.; Hoppe, R. T.; Wilson, L. D.; Beaven, A. W.; Horwitz, S.; Allen, P. B.; Barta, S. K.; Bohjanen, K.; Brammer, J. E.; Carter, J. B.; Comfere, N.; DeSimone, J. A.; Dusenbery, K.; Duvic, M.; Huen, A.; Jagadeesh, D.; Kelsey, C. R.; Khodadoust, M. S.; Lechowicz, M. J.; Mehta-Shah, N.; Moskowitz, A. J.; Olsen, E. A.; Poh, C.; Pro, B.; Querfeld, C.; Sauter, C.; Sokol, L.; Sokumbi, O.; Wilcox, R. A.; Zic, J. A.; Gru, A.; Hamadani, M.; Foss, F.
Title: ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome
Abstract: Introduction: Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma. While MF generally follows an indolent course, a subset of patients will experience progressive and/or treatment-refractory disease. SS is an aggressive cutaneous T-cell lymphoma associated with high morbidity and mortality secondary to immune compromise and opportunistic infection. Although allogeneic hematopoietic cell transplant (allo-HCT) is currently the only available potentially curative treatment modality for MF/SS and is included in the National Comprehensive Cancer Network and the American Society for Transplantation and Cellular Therapy treatment guidelines, there is no published guidance regarding referral criteria, timing and allo-HCT approach to help guide clinicians caring for these patients. Methods: Delphi survey of 32 specialists in dermatology (n = 9), transplant hematology/oncology (n = 10), nontransplant hematology/oncology (n = 8), and radiation oncology (n = 5) from across the United States. Consensus required agreement of ≥75% of participants. Results: Sixteen consensus statements were generated on 4 topics: 1) criteria for referral for consideration for allo-HCT, 2) allo-HCT preparative regimens and procedures, 3) disease status at the time of allo-HCT, and 4) multidisciplinary management in the pre- and post-transplant settings. Conclusion: These clinical practice guidelines provide a framework for decision-making regarding allo-HCT for MF/SS and highlight areas for future prospective investigation. © 2025 American Academy of Dermatology, Inc.
Keywords: stem cell transplant; cutaneous t-cell lymphoma; radiation oncology; dermatology; mycosis fungoides; reduced intensity; transplant; sezary syndrome; conditioning; allogeneic; total body irradiation; graft-versus-host; hematopoietic stem cell transplant; hematology/oncology; allogeneic stem cell transplant; myeloablative; total lymphoid irradiation; matched related donor; matched unrelated donor; total skin electron beam; tsebt
Journal Title: Journal of the American Academy of Dermatology
Volume: 93
Issue: 2
ISSN: 0190-9622
Publisher: Mosby Elsevier  
Publication status: Published
Date Published: 2025-08-01
Start Page: 387
End Page: 397
Language: English
DOI: 10.1016/j.jaad.2025.04.005
PUBMED: 40199382
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-105004893340&doi=10.1016%2fj.jaad.2025.04.005&partnerID=40&md5=5d21da763dbd33a16b6af50e19339bf6
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Steven M Horwitz
    666 Horwitz
  2. Alison Moskowitz
    358 Moskowitz
Related MSK Work